Natco Pharma

₹1484.3 33.7 | 2.3%

WEBSITE BSE:524816 NSE : NATCO PHARM 09 Dec, 12:30

Market Cap ₹26585 Cr.

Stock P/E 19.2

P/B 3.7

Current Price ₹1484.3

Book Value ₹ 399.2

Face Value 2

52W High ₹1638.4

Dividend Yield 0.64%

52W Low ₹ 752.6

Edit Ratio

Natco Pharma Research see more...

Overview Inc. Year: 1981Industry: Pharmaceuticals & Drugs

Natco Pharma Ltd is a pharmaceutical company. The Company is engaged in developing, production and advertising finished dosage formulations (FDF) and active pharmaceutical elements (APIs). The Company's segments include energetic prescription drugs factor, finished dosage formulations, job works, pharmacy and others. The Company's product categories consist of Domestic Formulations, International Formulations, API's and Blockbusters. The Company's merchandise include Thioplan, Anastronat, Capnat, Fulvenat, Kabanat, Natdox-LP, Alphalan, Bandrone, Bendit, Clokeran, Lenalid, Rapact, Temonat, X-Trant, Glatimer, Hepcinat, Lansoprazole, Letrozole, Granisetron, Rizatriptan IR, Imatinib, Salmeterol Xinafoate, Sertraline Form I, Natdac, Natzold, Tigi, Alprazolam, Chloroquine Phosphate, Ibandronate Sodium Monohydrate, Pantoprazole Sodium Sesquihydrate, Ondansetron Hydrochloride (Injectable Grade), Daclatasvir and Glatiramer Acetate. The Company manufactures over 20 merchandise underneath contract.

Natco Pharma Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Natco Pharma Quarterly Results

#(Fig in Cr.)	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Net Sales	885	432	493	898	1141	1031	759	1068	1363	1371
Other Income	34	21	21	29	20	29	37	42	48	64
Total Income	919	453	513	927	1160	1061	796	1110	1411	1435
Total Expenditure	489	337	387	559	613	573	491	571	558	567
Operating Profit	430	116	127	368	548	487	305	539	853	868
Interest	4	4	4	3	4	4	5	6	5	4
Depreciation	40	42	42	41	44	44	44	56	44	46
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	386	70	81	324	500	440	256	478	804	818
Provision for Tax	65	14	19	49	80	71	44	91	135	142
Profit After Tax	320	57	62	276	420	369	213	386	669	677
Adjustments	0	0	0	0	0	0	0	0	0	1
Profit After Adjustments	320	57	62	276	420	369	213	386	669	677
Adjusted Earnings Per Share	17.6	3.1	3.4	15.1	23.5	20.6	11.9	21.6	37.3	37.8

Natco Pharma Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Net Sales	739	730	1042	2020	2185	2095	1915	2052	1945	2707	3999	4561
Other Income	17	14	10	14	40	130	107	106	99	129	128	191
Total Income	756	745	1052	2034	2225	2225	2022	2158	2044	2836	4127	4752
Total Expenditure	560	524	777	1337	1256	1300	1332	1448	1681	1795	2247	2187
Operating Profit	196	220	275	697	969	925	690	710	363	1040	1880	2565
Interest	37	32	23	19	15	19	22	13	18	15	19	20
Depreciation	30	47	51	54	66	81	100	117	143	164	187	190
Exceptional Income / Expenses	0	-15	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	129	126	202	624	887	825	569	580	202	862	1674	2356
Provision for Tax	31	2	48	140	192	182	111	137	32	147	285	412
Profit After Tax	98	125	154	485	695	642	458	442	170	715	1388	1945
Adjustments	5	10	4	1	1	2	3	-2	0	0	0	1
Profit After Adjustments	103	135	157	486	696	644	461	441	170	715	1388	1945
Adjusted Earnings Per Share	6.2	8.1	9	27.9	37.7	35.3	25.3	24.2	9.3	39.2	77.6	108.6

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	48%	25%	14%	18%
Operating Profit CAGR	81%	38%	15%	25%
PAT CAGR	94%	46%	17%	30%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	92%	20%	21%	18%
ROE Average	26%	15%	14%	18%
ROCE Average	30%	18%	16%	21%

Natco Pharma Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	726	846	1296	1649	3072	3489	3774	4122	4264	4874	5853
Minority's Interest	7	5	5	4	4	2	11	2	0	0	0
Borrowings	95	97	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	55	22	28	38	47	83	118	143	135	101	61
Total Current Liabilities	312	414	493	627	592	729	685	526	710	683	973
Total Liabilities	1196	1384	1822	2318	3715	4303	4588	4792	5109	5657	6887
Fixed Assets	645	710	710	833	1019	1227	1584	2023	2312	2427	2491
Other Non-Current Assets	183	191	275	397	566	729	678	424	311	230	373
Total Current Assets	368	483	837	1087	2131	2347	2326	2345	2487	3000	4024
Total Assets	1196	1384	1822	2318	3715	4303	4588	4792	5109	5657	6887

Natco Pharma Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	10	10	-164	24	24	22	28	20	26	111	132
Cash Flow from Operating Activities	144	93	112	346	464	669	417	299	47	849	1212
Cash Flow from Investing Activities	-109	-115	-176	-299	-1116	-612	-167	-103	-5	-477	-1033
Cash Flow from Financing Activities	-35	29	154	-48	651	-51	-251	-186	35	-363	-247
Net Cash Inflow / Outflow	-0	7	91	-1	-1	6	-1	10	76	9	-68
Closing Cash & Cash Equivalent	10	12	-74	24	22	28	20	26	111	132	70

Natco Pharma Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	6.21	8.1	9.03	27.85	37.73	35.31	25.32	24.16	9.32	39.19	77.56
CEPS(Rs)	7.77	10.35	11.75	30.91	41.27	39.64	30.65	30.65	17.13	48.17	87.99
DPS(Rs)	1	1	1.25	6.75	8.25	6.25	6.75	5.25	4.5	5.5	9.5
Book NAV/Share(Rs)	43.9	50.91	73.91	93.63	165.22	189.49	206.04	224.88	233.44	267.06	326.99
Core EBITDA Margin(%)	24.08	27.72	24.59	33.09	42.16	34.79	28.31	28.97	11.89	31.64	40.43
EBIT Margin(%)	22.24	21.27	20.78	31.13	40.99	36.94	28.68	28.45	9.92	30.42	39.08
Pre Tax Margin(%)	17.32	17.01	18.66	30.24	40.29	36.1	27.63	27.81	9.12	29.91	38.63
PAT Margin (%)	13.17	16.81	14.22	23.48	31.57	28.12	22.26	21.23	7.67	24.83	32.05
Cash Profit Margin (%)	17.26	23.14	18.92	26.12	34.58	31.66	27.11	26.84	14.1	30.51	36.36
ROA(%)	8.62	9.69	9.58	23.43	23.05	16.02	10.3	9.43	3.43	13.29	22.13
ROE(%)	15.58	15.9	14.41	33.21	29.7	19.75	12.71	11.27	4.06	15.66	25.88
ROCE(%)	18.02	14.89	17.49	39.21	35.28	23.71	14.82	13.99	4.86	18.06	30.08
Receivable days	60.9	76.4	76.72	65.12	92.22	91.36	93.77	84.44	85.1	93.53	86.16
Inventory Days	80.17	98.47	97.54	62.41	65.25	77.28	96.38	118.77	128.47	95.32	60.81
Payable days	168.74	252.46	270.38	163.98	236.08	266.65	243.26	151.52	106.38	133.18	136.43
PER(x)	25.66	52.09	45.64	30.41	19.99	16.19	19.99	34.16	81.3	14.38	12.27
Price/Book(x)	3.63	8.29	5.58	9.05	4.57	3.02	2.46	3.67	3.24	2.11	2.91
Dividend Yield(%)	0.63	0.24	0.3	0.8	1.09	1.09	1.33	0.64	0.59	0.98	1
EV/Net Sales(x)	3.88	10.01	6.94	7.41	6.36	5.03	4.94	7.33	7.21	3.66	4.11
EV/Core EBITDA(x)	14.62	33.18	26.3	21.46	14.35	11.39	13.71	21.19	38.67	9.52	8.75
Net Sales Growth(%)	11.86	-1.14	42.69	93.82	8.15	-4.13	-8.57	7.16	-5.23	39.2	47.72
EBIT Growth(%)	28.74	-4.51	41.91	186.5	40.4	-6.49	-30.07	0.46	-62.91	298.54	93.14
PAT Growth(%)	48.91	27.35	22.94	215.69	43.37	-7.59	-28.69	-3.43	-61.57	320.76	94.09
EPS Growth(%)	35.6	30.39	11.45	208.47	35.49	-6.43	-28.3	-4.58	-61.44	320.76	97.88
Debt/Equity(x)	0.33	0.37	0.09	0.14	0.06	0.11	0.08	0.06	0.09	0.03	0.06
Current Ratio(x)	1.18	1.17	1.7	1.74	3.6	3.22	3.39	4.46	3.5	4.39	4.14
Quick Ratio(x)	0.61	0.65	0.97	1.18	2.86	2.5	2.63	3.04	2.49	3.35	3.47
Interest Cover(x)	4.52	4.99	9.8	34.75	58.61	43.73	27.45	44.58	12.42	60.44	88.16
Total Debt/Mcap(x)	0.09	0.04	0.02	0.02	0.01	0.04	0.03	0.02	0.03	0.02	0.02

Natco Pharma Shareholding Pattern

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	48.8	48.8	48.82	48.84	49.76	49.71	49.71	49.71	49.71	49.62
FII	11.65	11.67	11.72	11.91	11.02	12.82	13.72	16.14	17.45	17.51
DII	15.29	14.3	14.93	15.37	15.15	14.01	11.25	9.7	7.86	6.75
Public	24.25	25.23	24.53	23.87	24.07	23.46	25.32	24.46	24.97	26.12
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	8.91	8.91	8.91	8.91	8.91	8.9	8.9	8.9	8.9	8.89
FII	2.13	2.13	2.14	2.17	1.97	2.3	2.46	2.89	3.13	3.14
DII	2.79	2.61	2.73	2.81	2.71	2.51	2.01	1.74	1.41	1.21
Public	4.43	4.61	4.48	4.36	4.31	4.2	4.54	4.38	4.47	4.68
Others	0	0	0	0	0	0	0	0	0	0
Total	18.26	18.26	18.26	18.25	17.91	17.91	17.91	17.91	17.91	17.91

Pros

Company is almost debt free.

Cons

Promoter holding is low: 49.62%.
Debtor days have increased from 133.18 to 136.43days.
Stock is trading at 3.7 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Natco Pharma News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Natco Pharma

Add Watchlist

Natco Pharma Research see more...

Overview Inc. Year: 1981Industry: Pharmaceuticals & Drugs

Natco Pharma Share Price

Alert Data

Quarterly Price

Peer Comparison

Natco Pharma Quarterly Results

Natco Pharma Profit & Loss

Growth Rates

Natco Pharma Balance Sheet

Natco Pharma Cash Flow

Natco Pharma Ratios

Natco Pharma Shareholding Pattern

Natco Pharma News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!